Sutro Biopharma, Inc. STRO
Sutro Biopharma, Inc. (Nasdaq: STRO) is an oncology drug developer. Its lead program, STRO-004 (tissue factor-directed ADC), is in Phase 1 for advanced TF-expressing solid tumors. Its next catalyst on record is STRO-227 (PTK7 dpADC): IND submission (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: STRO-227 (PTK7 dpADC) — IND submission (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| STRO-004 (TF ADC) | advanced solid tumors (NSCLC, HNSCC, cervical, CRC, PDAC, endometrial, bladder, gastric/esophageal) | antibody | Phase 1 |
| Astellas-partnered iADC (first program; partner-sponsored) | oncology | antibody | Phase 1 |
| STRO-006 (ITGb6 ADC) | solid tumors | antibody | Pre-clinical |
| STRO-227 (PTK7 dual-payload ADC) | solid tumors | antibody | Pre-clinical |
Recent results and decisions
- Aug 12, 2026positive Early Phase 1 data: confirmed and ongoing unconfirmed partial responses across three tumor types at 3-4 mg/kg (n=49 enrolled), 6% AE discontinuation rate, MTD not yet defined.
Multiple responses, including confirmed and ongoing unconfirmed partial responses, across three tumor types in RECIST-evaluable patients to date; including pancreatic cancer, head and neck cancer, and non-small cell lung cancer at dose levels 3-4 mg/kg
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.